10-Q: Bone Biologics Q3 2025: Cash Up, Losses Narrow, Going Concern Remains

Bone Biologics Corporation reported a narrower net loss and increased cash reserves for Q3 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, was $2.42 million, a 6.42% improvement from $2.59 million in the same period of 2024.
• Cash balance significantly increased to $6.05 million as of September 30, 2025, up from $3.33 million at December 31, 2024.
• Operating expenditures for the next twelve months are estimated at $6.9 million.
• Available cash is expected to fund operations into the fourth quarter of 2026.
• Research and development expenses decreased by 21.72% to $802,994 for the nine months ended September 30, 2025, primarily due to the timing of clinical trials.
• General and administrative expenses increased by 3.69% to $1.70 million for the nine months ended September 30, 2025, mainly due to higher stock option compensation for directors.
• The company completed a public offering in June 2025, raising net proceeds of $4.35 million, and also utilized an At The Market (ATM) offering program for an additional $0.35 million in net proceeds.
• A 1-for-6 reverse stock split was effected on June 10, 2025.
• Accumulated losses since inception total approximately $87.4 million as of September 30, 2025.
• The pilot clinical study for NB1 bone graft device in Australia is ongoing, evaluating safety and effectiveness in up to 30 adult subjects.

Sentiment

Score: 3

Explanation: While the company successfully raised capital and reduced its net loss, the persistent 'going concern' warning and lack of revenue generation indicate significant underlying financial instability and high risk. The cash runway extension is positive but contingent on future financing and successful clinical development.

Positives

• Net loss for the nine months ended September 30, 2025, decreased by 6.42% to $2.42 million compared to $2.59 million in the prior year.
• Cash balance increased significantly to $6.05 million at September 30, 2025, from $3.33 million at December 31, 2024.
• Net cash used in operating activities decreased to $1.98 million for the nine months ended September 30, 2025, from $2.77 million in the prior year, partly due to the absence of a legal settlement payment.
• Successful capital raises in June 2025 and through the ATM facility provided $4.70 million in financing activities.
• Available cash is expected to fund operations into the fourth quarter of 2026, extending the cash runway.
• The pilot clinical study for NB1 in Australia is progressing, with the study design previously agreed upon by the FDA for progression to a pivotal clinical trial in the United States.
• A patent application for rhNELL-1 polypeptide for treating bone conditions was submitted in Q2 2025.

Negatives

• The company has no significant operating history and has not generated revenues from planned operations.
• Accumulated losses since inception total approximately $87.4 million as of September 30, 2025.
• The company incurred a net loss of $2.42 million and used $1.98 million in net cash from operating activities during the nine months ended September 30, 2025.
• These factors raise substantial doubt about the company's ability to continue as a going concern within one year.
• The independent registered public accounting firm also expressed substantial doubt about the company's ability to continue as a going concern in its audit report for the year ended December 31, 2024.
• Future financing may not be available on satisfactory terms or could cause substantial dilution for stockholders.
• Operating expenditures for the next twelve months are estimated at $6.9 million, indicating continued significant cash burn.

Risks

• Inability to raise additional capital to fund operations.
• Impact of inflation, rising interest rates, governmental responses, and possible recession.
• Challenges in obtaining Food and Drug Administration (FDA) and other regulatory authorization to market drug and biological products.
• Uncertainty regarding the successful completion of clinical trials.
• Inability to achieve regulatory authorization to market the lead product NELL-1/DBM.
• Uncertainty regarding the success of patent applications.
• Reliance on third-party manufacturers for drug products.
• Lack of market acceptance of products.
• Dependence on licenses for certain products, specifically the exclusive license from UCLA TDG for NELL-1.
• Reliance on the expected growth in demand for products.
• Exposure to product liability and defect claims.
• Challenges in the development of a public trading market for securities.
• Adverse effects from macroeconomic and geopolitical events such as tariffs, inflation, and ongoing conflicts.
• Deterioration of equity and credit markets making future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive.
• Patents issued to or licensed by the company may be challenged, invalidated, rendered unenforceable, or circumvented.
• Problems in clinical trials that could cause the company or the FDA to delay or suspend clinical trials.
• UCLA TDG has the right to terminate or reduce the license to a non-exclusive license if the company does not meet certain diligence milestone deadlines.

Future Outlook

The company anticipates continued substantial investment in development activities for NELL-1 as it prepares for a pivotal clinical study in the future. It will continue to attempt to raise additional debt and/or equity financing to fund future operations and provide additional working capital, with current cash expected to fund operations into the fourth quarter of 2026.

Management Comments

• We anticipate continued substantial investment in development activities for NELL-1 as we prepare for our pivotal clinical study in the future.
• We will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital.
• If cash resources are insufficient to satisfy our on-going cash requirements, we will be required to scale back or discontinue our product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require us to relinquish rights to our technology or substantially reduce or discontinue our operations entirely.

Industry Context

Bone Biologics operates in the highly regulated medical device and biotechnology sector, specifically focusing on bone regeneration for spinal fusion. The development of its lead product, NELL-1/DBM, as a device/drug combination product, places it within a segment requiring extensive preclinical and clinical testing and stringent FDA approval processes. The ongoing pilot clinical study in Australia and plans for a pivotal U.S. trial indicate a progression typical for clinical-stage entities in this industry, where significant capital investment and long development timelines are standard. The company's reliance on licensing agreements and patent protection is also characteristic of the intellectual property-intensive nature of the biotech industry.

Comparison to Industry Standards

• The company's status as a clinical-stage entity with no revenue generation is common for early-stage biotechnology and medical device companies focused on product development and regulatory approval.
• The requirement for an FDA-approved Pre-Market Approval (PMA) application for NELL-1/DBM as a device/drug combination product is a standard, rigorous regulatory pathway for novel medical technologies in the U.S.
• The substantial accumulated deficit of $87.4 million and ongoing net losses are typical for companies in the research and development phase, which require significant investment before potential commercialization.
• The need for continuous capital raises through equity offerings and ATM programs is a common financing strategy for pre-revenue biotech firms to fund extensive clinical trials and operational expenses.
• The expressed "substantial doubt about the company's ability to continue as a going concern" is a critical disclosure for early-stage companies with significant burn rates and no commercial products, highlighting the inherent financial risks in this industry.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on its business, results of operations, financial condition or cash flows.
• Litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings; risk of value loss if the company cannot continue as a going concern; potential for long-term gains if NELL-1/DBM successfully reaches commercialization.
• Employees: Continued employment and potential for stock-based compensation are tied to the company's ability to secure ongoing financing and achieve product development milestones.
• Customers (future): Potential for a novel bone regeneration product (NB1) for spinal fusion, offering improved outcomes for patients with degenerative disc disease.
• Creditors: Risk associated with the company's going concern uncertainty and accumulated deficit.
• UCLA TDG: Continued receipt of annual maintenance fees and potential for significant milestone payments and royalties upon successful product development and commercialization.

Next Steps

• Continue development activities for the NELL-1/DBM lead product.
• Prepare for a pivotal clinical study in the United States for the NB1 bone graft device.
• Seek FDA approval for the pre-market approval (PMA) application for NELL-1/DBM.
• Attempt to raise additional debt and/or equity financing to fund future operations and provide additional working capital.
• Pursue patent approval for the rhNELL-1 polypeptide for treating bone conditions.
• Meet diligence milestone deadlines under the UCLA TDG license agreement to avoid termination or reduction of exclusivity.

Key Dates

Recommendation

Despite a narrower net loss and increased cash from recent capital raises, the company explicitly states 'substantial doubt about its ability to continue as a going concern' and has accumulated $87.4 million in losses with no revenue. The estimated $6.9 million in operating expenditures for the next 12 months, while covered by current cash into Q4 2026, still necessitates further capital raises, which will likely lead to significant shareholder dilution. The long and uncertain path to FDA approval and commercialization for its lead product, coupled with the inherent risks of clinical trials and patent success, makes this a highly speculative investment with significant downside risk. A seasoned investor would likely view the going concern warning and continuous need for dilutive financing as a strong signal to exit or avoid the stock.

Keywords

Bone Biologics, BBLG, NELL-1, Spinal Fusion, Bone Regeneration, Medical Device, Clinical Trial, FDA Approval, PMA, NB1 bone graft, Degenerative Disc Disease, Biotechnology, Biologics, SEC Filing, 10-Q, Going Concern, Capital Raise, Warrants, Stock Split